CClinicalTrials.gg
Not yet recruitingNCT06831695Updated Feb 18, 2025

Comparison of Surgical Outcomes of Craniotomy and Craniectomy in Posterior Fossa Lesions

An interventional study of Craniotomy and Craniectomy in Posterior Fossa Lesion, sponsored by University of Health Sciences Lahore. Not yet recruiting. Open to participants aged 7 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by University of Health Sciences Lahore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
7 Years to 70 Years
Sex
All
01

Study summary

The purpose of this randomized controlled trial is to compare the surgical outcomes of craniotomy and craniectomy among patients with posterior fossa lesions. The study aims to determine differences in post-operative complications, hospital stay duration, and patient recovery between the two surgical techniques.

Read the detailed description

Patients diagnosed with posterior fossa lesions will be randomly assigned into two groups. Group A will undergo craniotomy, where the bone flap is replaced after dural closure, while Group B will undergo craniectomy, where the bone is permanently removed. Outcomes will be assessed based on post-operative complications such as CSF leakage, pseudomeningocele formation, post-operative headache, and length of hospital stay. The study aims to provide evidence to determine the superior surgical approach in terms of patient outcomes and healthcare cost reduction.

02

Conditions studied

  • Posterior Fossa Lesion

Keywords

  • Craniotomy
  • Craniectomy
  • Neurosurgery
  • Posterior Fossa
  • Brain Tumors
03

In context

Lead sponsor

University of Health Sciences Lahore is the lead sponsor of 77 studies on the registry; 49 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients diagnosed with posterior fossa lesions
  • Age range: 7-70 years
  • Patients with cerebellar hematoma (traumatic or spontaneous)

Exclusion criteria

Exclusion Criteria:

  • Previous posterior fossa surgery
  • Brainstem hematoma
  • Tumors involving the overlying dura or bone
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Group A: Craniotomy

    This procedure involves creating a single free bone flap using high-speed drills. The bone is repositioned and secured using mini plates or sutures after the surgical intervention is completed. Post-operative monitoring will include assessment for CSF leakage, wound healing, and neurological recovery.

    Procedure: Craniotomy

  • Active comparator
    Group B: Craniectomy

    In this approach, the bone is removed in pieces using rongeurs, leaving an open dural surface without replacement of the bone. The dura is closed with sutures, and dural augmentation may be performed as needed. Post-operative assessment will focus on complications such as pseudomeningocele, CSF leakage, and extended hospital stays.

    Procedure: Craniectomy

Interventions

  • ProcedureCraniotomy

    Intervention: Bone flap replaced after dural closure Additional Information: This procedure involves creating a single free bone flap using high-speed drills. The bone is repositioned and secured using mini plates or sutures after the surgical intervention is completed. Post-operative monitoring will include assessment for CSF leakage, wound healing, and neurological recovery.

  • ProcedureCraniectomy

    Intervention: Bone permanently removed Additional Information: In this approach, the bone is removed in pieces using rongeurs, leaving an open dural surface without replacement of the bone. The dura is closed with sutures, and dural augmentation may be performed as needed. Post-operative assessment will focus on complications such as pseudomeningocele, CSF leakage, and extended hospital stays.

06

What researchers measure

Primary outcomes

  1. Incidence of CSF leakage

    Definition: CSF leakage is defined as the presence of clear fluid discharge from the surgical site, confirmed via clinical examination and biochemical analysis of β-2 transferrin. Measurement: Evaluated by clinical assessment at routine follow-ups and imaging studies when indicated.

    Time frame: Up to 6 months post-surgery

  2. Occurrence of pseudomeningocele

    Definition: Pseudomeningocele is defined as an abnormal collection of cerebrospinal fluid in the surgical site, detected through physical examination and confirmed by imaging techniques such as MRI or CT scan. Measurement: Follow-up visits at 1, 3, and 6 months post-surgery.

    Time frame: Up to 6 months post-surgery

  3. Severity of post-operative headache

    Definition: Post-operative headache will be assessed using the Catalano grading system, categorizing severity from 0 (no headache) to 4 (severe, refractory to medication). Measurement: Self-reported patient evaluations at each follow-up visit.

    Time frame: Immediately post-surgery, at 3 months, and at 6 months post-surgery

  4. Length of hospital stay

    Definition: The total number of days a patient remains hospitalized post-surgery, including any extended stay due to complications. Measurement: Recorded from hospital admission to discharge.

    Time frame: From immediate post-surgery until hospital discharge, assessed up to 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06831695
Lead sponsor
University of Health Sciences Lahore
Responsible party
Dr. Birat Thapa Magar (Principal Investigator, University of Health Sciences Lahore) — Principal investigator
First posted
Feb 18, 2025
Start date
Mar 4, 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Feb 18, 2025

Study contacts

Dr. Birat Thapa Magar, Post Graduate Resident
Contact
biratjmagar.5@gmail.com
+923057895437

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion